Effects of methotrexate in a toluene diisocyanate-induced allergic rhinitis rat model

Yıl 2018, Cilt: 28 Sayı: 1, 34 - 39, 05.03.2018

Sibel Alicura Tokgöz Gökçe Şimşek Erkan Vuralkan Ömer Bayır Fulya Köybaşıoğlu Murat Çalışkan Ömer Beşaltı İstemihan Akın

Öz

Objectives: This study aims to investigate the therapeutic effect of low-dose topical administration of methotrexate MTX in a toluene diisocyanate TDI -induced allergic rhinitis rat model. Materials and Methods: The experiments were performed on 18 healthy male Wistar albino rats weighing between 250-270 g. Rats were divided into four study groups: control group n=5 , sham group n=3 , steroid group n=5 , and MTX group n=5 . After the drugs were administered, multiple biopsies were taken bilaterally from the nasal mucosal areas and evaluated histologically for fibrosis, loss of cilia and goblet cells, edema, squamous cell metaplasia, and vascular proliferation. Results: Fibrosis, loss of cilia cells, edema, and vascular proliferation were significantly lower in both MTX and steroid groups than in the control group p<0.05 . There were no statistically significant differences with respect to histopathological parameters between the steroid group and the MTX group p>0.05 . There were no statistically significant differences with respect to loss of goblet cells and squamous cell metaplasia among the studied groups p>0.05 . Conclusion: Methotrexate may be an alternative or adjuvant therapeutic agent in allergic rhinitis.

Anahtar Kelimeler

Allergic rhinitis, methotrexate, toluene diisocyanate

Kaynakça

• Bousquet J, Schünemann HJ, Zuberbier T, Bachert C, Baena-Cagnani CE, Bousquet PJ, et al. Development and implementation of guidelines in allergic rhinitis-an ARIA-GA2LEN paper. Allergy 2010;65:1212-21.
• Jang TY, Jung AY, Kyung TS, Kim DY, Hwang JH, Kim YH. Anti-allergic effect of luteolin in mice with allergic asthma and rhinitis. Cent Eur J Immunol 2017;42:24-29.
• Baroody FM, Brown D, Gavanescu L, DeTineo M, Naclerio RM. Oxymetazoline adds to the effectiveness of fluticasone furoate in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol 2011;127:927-34.
• Marder W, McCune WJ. Advances in immunosuppressive therapy. Semin Respir Crit Care Med 2007;28:398-417.
• Chaabane S, Marzouk S, Akrout R, Ben Hamad M, Achour Y, Rebai A, et al. Genetic Determinants of Methotrexate Toxicity in Tunisian Patients with Rheumatoid Arthritis: A Study of Polymorphisms Involved in the MTX Metabolic Pathway. Eur J Drug Metab Pharmacokinet 2016;41:385-93.
• Domingo C, Moreno A, Amengual MJ, Comet R, Luján M. Twelve years’ experience with methotrexate for GINA treatment step 5 asthma patients. Curr Med Res Opin 2009;25:367-74.
• Tanaka K, Okamoto Y, Nagaya Y, Nishimura F, Takeoka A, Hanada S, et al. A nasal allergy model developed in the guinea pig by intranasal application of 2,4-toluene diisocyanate. Int Arch Allergy Appl Immunol 1988;85:392-7.
• Ercan I, Cakir BO, Başak T, Ozbal EA, Sahin A, Balci G, et al. Effects of topical application of methotrexate on nasal mucosa in rats: a preclinical assessment study. Otolaryngol Head Neck Surg 2006;134:751-5.
• Muti AD, Pârvu AE, Muti LA, Moldovan R, Mureşan A. Vitamin E effect in a rat model of toluene diisocyanate- induced asthma. Clujul Med 2016;89:499-505.
• Ban M, Morel G, Langonné I, Huguet N, Pépin E, Binet S. TDI can induce respiratory allergy with Th2-dominated response in mice. Toxicology 2006;218:39-47.
• May JR, Dolen WK. Management of Allergic Rhinitis: A Review for the Community Pharmacist. Clin Ther 2017;39:2410-2419.
• Shimizu S, Hattori R, Majima Y, Shimizu T. Th2 cytokine inhibitor suplatast tosilate inhibits antigen-induced mucus hypersecretion in the nasal epithelium of sensitized rats. Ann Otol Rhinol Laryngol 2009;118:67-72.
• Chang DY, Joo YH, Kim SJ, Kim JH, Jung MH, Kim DW, et al. Therapeutic effects of intranasal cyclosporine for eosinophilic rhinosinusitis with nasal polyps in a mouse model. Am J Rhinol Allergy 2015;29:e29-32.
• Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev 2005;57:163-72.
• Morabito L, Montesinos MC, Schreibman DM, Balter L, Thompson LF, Resta R, et al. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides. J Clin Invest 1998;101:295-300.
• Matsune S, Ohori J, Yoshifuku K, Kurono Y. Effect of vascular endothelial growth factor on nasal vascular permeability. Laryngoscope 2010;120:844-8.
• Yamashita T, Terada N, Hamano N, Kishi H, Kobayashi N, Kotani Y, et al. Involvement of vascular endothelial growth factor in nasal obstruction in patients with nasal allergy. Allergol Int 2000;49:183-8.
• Park SK, Kim HI, Yang YI, Hur DY. Effects of methotrexate on vascular endothelial growth factor, angiopoietin 1, and angiopoietin 2 in nasal polyps. Am J Rhinol Allergy 2011;25:e129-32.
• Buyukozturk S, Gelincik A, Aslan I, Aydin S, Colakoglu B, Dal M. Methotrexate: can it be a choice for nasal polyposis in aspirin exacerbated respiratory disease? J Asthma 2009;46:1037-41.
• Corrigan CJ, Shiner R, Shakur BH, Ind PW. Methotrexate therapy in asthma increases T cell susceptibility to corticosteroid inhibition. Clin Exp Allergy 2003;33:1090-6.
• Goecke IA, Alvarez C, Henríquez J, Salas K, Molina ML, Ferreira A, et al. Methotrexate regulates the expression of glucocorticoid receptor alpha and beta isoforms in normal human peripheral mononuclear cells and human lymphocyte cell lines in vitro. Mol Immunol 2007;44:2115-23.
• Bilocca D, Hargadon B, Pavord ID, Green RH, Brightling CE, Bradding P, et al. The role of oral methotrexate as a steroid sparing agent in refractory eosinophilic asthma. Chron Respir Dis 2018;15:85-87.
• Nakaya M, Dohi M, Okunishi K, Nakagome K, Tanaka R, Imamura M, et al. Prolonged allergen challenge in murine nasal allergic rhinitis: nasal airway remodeling and adaptation of nasal airway responsiveness. Laryngoscope 2007;117:881-5.
• Canakcioglu S, Tahamiler R, Saritzali G, Alimoglu Y, Isildak H, Guvenc MG, et al. Evaluation of nasal cytology in subjects with chronic rhinitis: a 7-year study. Am J Otolaryngol 2009;30:312-7.
• Berger G, Marom Z, Ophir D. Goblet cell density of the inferior turbinates in patients with perennial allergic and nonallergic rhinitis. Am J Rhinol 1997;11:233-6.
• Kavanaugh A, Broide DH. Immunomodulators. In: Adkinson NF, Bochner BS, Busse WW, Holgate ST, Lemanske RF, Simons FER, editors. Middleton’s Allergy Principles & Practice. 7th ed. China: Elsevier; 2009. p. 1643-56.